KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Depreciation and Depletion (2023 - 2024)

Historic Depreciation and Depletion for Gsk (GSK) over the last 7 years, with Q4 2015 value amounting to $1.4 billion.

  • Gsk's Depreciation and Depletion rose 952.94% to $1.4 billion in Q4 2015 from the same period last year, while for Dec 2015 it was $5.2 billion, marking a year-over-year increase of 3427.71%. This contributed to the annual value of $1.3 billion for FY2018, which is 10.59% up from last year.
  • Gsk's Depreciation and Depletion amounted to $1.4 billion in Q4 2015, which was up 952.94% from $1.2 billion recorded in Q4 2014.
  • Gsk's Depreciation and Depletion's 5-year high stood at $1.4 billion during Q4 2012, with a 5-year trough of $33.0 million in Q4 2011.
  • In the last 5 years, Gsk's Depreciation and Depletion had a median value of $1.2 billion in 2014 and averaged $1.0 billion.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first tumbled by 9817.72% in 2011, then surged by 413815.01% in 2012.
  • Quarter analysis of 5 years shows Gsk's Depreciation and Depletion stood at $33.0 million in 2011, then soared by 4138.15% to $1.4 billion in 2012, then fell by 15.27% to $1.2 billion in 2013, then rose by 4.28% to $1.2 billion in 2014, then increased by 9.53% to $1.4 billion in 2015.
  • Its Depreciation and Depletion stands at $1.4 billion for Q4 2015, versus $1.2 billion for Q4 2014 and $1.2 billion for Q4 2013.